Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Clin Microbiol Infect. 2019 May;25(5):620-622. doi: 10.1016/j.cmi.2018.08.002. Epub 2018 Aug 11.
Antimicrobial agents are commonly used in ambulatory care settings. Our objective was to examine national-level patterns of contraindications between oral antibacterial or antifungal agents and patients' other oral medications in the US ambulatory care setting.
This cross-sectional study included multiple year pooled data (2003-2011) from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department). Visits by adults (age ≥18 years) in ambulatory settings in the United States who were prescribed oral antibacterial or antifungal agents were evaluated for potential drug-drug interaction (DDI) contraindications. Findings with relative standard error >30% or unweighted sample size <30 were not reported because these were deemed unreliable estimates.
From 2003 to 2011, there were 1 235 000 outpatient visits (proportion = 0.52%; 95% confidence interval (CI), 0.29-0.74) in which a patient was prescribed an antimicrobial agent associated with a contraindicated DDI. The most prevalent antimicrobials with contraindicated combination among outpatients were simultaneous use of macrolide-containing products (erythromycin or clarithromycin) with statin medication-containing products (simvastatin or lovastatin) (841 864 visits, proportion = 1.91%; 95% CI, 0.96-2.86). The next most common combination was use of fluoroquinolones with antiarrhythmic agents (amiodarone, sotalol, quinidine or procainamide) (365 622 visits, proportion = 0.19%; 95% CI, 0.06-0.32).
Providers should be aware of potential contraindicated DDIs when prescribing antibiotics, especially macrolides and fluoroquinolones.
抗菌药物在门诊环境中被广泛使用。本研究旨在调查美国门诊环境中口服抗菌或抗真菌药物与患者其他口服药物之间禁忌的全国水平模式。
本横断面研究纳入了 2003 年至 2011 年期间国家门诊医疗调查和国家医院门诊医疗调查(NHAMCS 门诊部门)的多年度合并数据。对美国门诊环境中接受口服抗菌或抗真菌药物治疗的成年人(年龄≥18 岁)的就诊情况进行评估,以确定潜在的药物相互作用(DDI)禁忌。相对标准误差>30%或未加权样本量<30 的结果未予报告,因为这些结果被认为是不可靠的估计值。
2003 年至 2011 年间,有 1235 万门诊就诊(比例为 0.52%;95%置信区间(CI),0.29-0.74),其中患者接受了与禁忌 DDI 相关的抗菌药物治疗。门诊患者中最常见的与禁忌组合的抗菌药物是同时使用含大环内酯类产品(红霉素或克拉霉素)和含他汀类药物的产品(辛伐他汀或洛伐他汀)(841864 次就诊,比例为 1.91%;95%CI,0.96-2.86)。下一个最常见的组合是使用氟喹诺酮类药物与抗心律失常药物(胺碘酮、索他洛尔、奎尼丁或普鲁卡因胺)(365622 次就诊,比例为 0.19%;95%CI,0.06-0.32)。
当开具抗生素处方时,特别是大环内酯类和氟喹诺酮类药物时,医生应注意潜在的禁忌药物相互作用。